Kazia Therapeutics (NASDAQ: KZIA)

Currency in USD

Last close As at 09/06/2023


0.04 (3.13%)

Market capitalisation


Kazia Therapeutics’ lead asset paxalisib (a PI3K inhibitor that can cross the blood brain barrier (BBB), licensed from Genentech) is in a pivotal study for glioblastoma (GBM) and in early-stage studies in childhood brain cancers, DIPG and AT/RT. Phase I EVT801 is an inhibitor of VEGFR3.

GBM is the most common primary cancer of the brain with c 12,500–13,000 new cases reported in the United States per year. There are very limited treatment options for GBM and the survival rate is very low. Paxalisib is currently being developed for use in the adjuvant setting after initial resection and radiation treatment. EVT801 will target the multibillion-dollar angiogenesis cancer market.



Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Iain Ross


  • John Friend


  • Karen Krumeich


Balance Sheet

Forecast net debt (US$m)


Forecast gearing ratio (%)


Share Price Performance

Price Performance
% 1M 3M 12M
Actual 7.1 28.2 (77.5)
Relative 3.2 19.1 (78.4)
52 week high/low US$6.0/US$0.5


Kazia is developing the anti-cancer compound paxalisib (GDC-0084) for GBM and other brain cancers. Paxalisib is a PI3K inhibitor, with activity across a wide range of tumor types. Paxalisib, unlike other drugs of this class, can cross the BBB, opening the potential to treat cancers of the brain. Paxalisib has not progressed to stage 2 of the Phase III GBM AGILE study, although the first stage (~150 patients) remains ongoing, with final data expected in H2 CY23. A Phase II DIPG study (paxalisib in combination with ONC201) is also ongoing with initial data anticipated in CY23. In March 2023, Kazia announced a collaboration with the Australian and New Zealand Children’s Haematology/Oncology Group investigating paxalisib (with chemotherapy) in children with advanced solid tumors (Phase II). In May, CMO John Friend was appointed as the new CEO. The Q323-end cash balance was A$8m.

Y/E Jun Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (fd) (c) P/E (x) P/CF (x)
2021A 10.7 (3.1) (3.1) (25.09) N/A N/A
2022A 0.0 (14.9) (14.9) (110.57) N/A N/A
2023E 0.0 (19.0) (19.0) (111.41) N/A N/A
2024E 10.8 (17.2) (17.2) (82.84) N/A N/A

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free